ENTITY
Xiamen Amoytop Biotech Co Ltd

Xiamen Amoytop Biotech Co Ltd (688278 CH)

8
Analysis
Health CareChina
Xiamen Amoytop Biotech Co., Ltd. operates as a drug development company. The Company develops and sells protein drugs, interferon drugs, and other products. Xiamen Amoytop Biotech markets its products primarily throughout China with limited overseas.
more
Refresh
19 Oct 2023 08:55

Pre-IPO VISEN Pharmaceuticals - The Product Pipeline and the Key Risks

VISEN’s pipeline has strength, but fierce competition/VBP/increasingly stringent regulatory environment will bring challenges to...

Logo
390 Views
Share
27 Nov 2021 10:38

STAR50 Index Rebalance: Oops! They Did It Again...

There are 5 changes at the Dec rebalance as the index committee have continued to use a 6 month minimum listing history even though the methodology...

Logo
466 Views
Share
15 Oct 2021 07:30

STAR50 Index Rebalance Dec 21 Preview: Big Turnover & Moderate Impact

We see 5 potential changes to the STAR50 index in Dec and expect a 12 month minimum listing history to be used. The potential inclusions should...

Logo
388 Views
Share
08 Sep 2021 10:33

STAR50 Index Rebalance December Preview: 12 Month or 6 Month Listing History, That Is The Question

CSI and SSE could start to use a 12 month minimum listing history requirement from the December rebalance. One-way turnover could be in excess of...

Logo
280 Views
Share
bullishI-Mab
29 Mar 2021 09:05

I-Mab (IMAB US) - Insights On Core Products TJC4, TJ202 and TJ101

As I-MAB has come to a key phase from R&D to commercialization, this article analyzed both the strength and the concerns for its core products...

Logo
197 Views
Share
x